Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups-Reference-Cited by-同舟云学术

Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups

Published:2015-11 Issue:11 Volume:21 Page:1883-1887
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Deeg H. Joachim,Bredeson Christopher,Farnia Stephanie,Ballen Karen,Gupta Vikas,Mesa Ruben A.,Popat Uday,Hari Parameswaran,Saber Wael,Seftel Matthew,Tamari Roni,W. Petersdorf Effie

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference38 articles.

1. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011;Deadmond;J Cancer Res Clin Oncol,2015

2. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases;Mesa;Blood,2005

3. Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms;Kennedy;Blood,2013

4. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis;Verstovsek;N Engl J Med,2012

5. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis;Harrison;N Engl J Med,2012

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Programmed death‐ligand 1 expression in patients with primary or secondary myelofibrosis;Cancer Reports;2024-09

2. Transplant Outcomes in Myelofibrosis: Impact of Donor Type [Cord Blood Grafts Supported by CD34+ selected Cells (Haplo-Cord) vs Matched Donors];Transplantation and Cellular Therapy;2024-09

3. Phenotypic characterization of disease‐initiating stem cells in JAK2‐ or CALR‐mutated myeloproliferative neoplasms;American Journal of Hematology;2023-03-09

4. Myeloproliferative Disorders;Holland‐Frei Cancer Medicine;2022-10-21

5. Impact of molecular profiling on the management of patients with myelofibrosis;Cancer Treatment Reviews;2022-09